

Yong-Bok Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2776602/publications.pdf>

Version: 2024-02-01

103
papers

2,229
citations

279798

23
h-index

243625

44
g-index

103
all docs

103
docs citations

103
times ranked

3099
citing authors

#	ARTICLE	IF	CITATIONS
1	Toxicokinetic studies of di-isobutyl phthalate focusing on the exploration of gender differences in rats. <i>Chemosphere</i> , 2022, 286, 131706.	8.2	6
2	Population pharmacokinetic analysis of lornoxicam in healthy Korean males considering creatinine clearance and CYP2C9 genetic polymorphism. <i>Journal of Pharmaceutical Investigation</i> , 2022, 52, 109-127.	5.3	10
3	Population Pharmacokinetic (Pop-PK) Analysis of Torsemide in Healthy Korean Males Considering CYP2C9 and OATP1B1 Genetic Polymorphisms. <i>Pharmaceutics</i> , 2022, 14, 771.	4.5	8
4	Human risk assessment of 4-n-nonylphenol (4-n-NP) using physiologically based pharmacokinetic (PBPK) modeling: analysis of gender exposure differences and application to exposure analysis related to large exposure variability in population. <i>Archives of Toxicology</i> , 2022, 96, 2687-2715.	4.2	5
5	Simultaneous determination of fourteen components of Gumiganghwal-tang tablet in human plasma by UPLC-ESI-MS/MS and its application to pharmacokinetic study. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 444-457.	5.3	8
6	Simultaneous determination of asarinin, eudesmol, and wogonin in rats using ultraperformance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies following administration of standards and Gumiganghwal-tang. <i>Biomedical Chromatography</i> , 2021, 35, e5021.	1.7	5
7	In vivo and in vitro studies of Banhahoobak-tang tablets using UPLC-ESI-MS/MS with polarity switching. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 196, 113931.	2.8	0
8	Pharmacokinetic Changes According to Single or Multiple Oral Administrations of Socheongryong-Tang to Rats: Presented as a Typical Example of Changes in the Pharmacokinetics Following Multiple Exposures to Herbal Medicines. <i>Pharmaceutics</i> , 2021, 13, 478.	4.5	0
9	Human risk assessment of di-isobutyl phthalate through the application of a developed physiologically based pharmacokinetic model of di-isobutyl phthalate and its major metabolite mono-isobutyl phthalate. <i>Archives of Toxicology</i> , 2021, 95, 2385-2402.	4.2	8
10	Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects. <i>Pharmaceutics</i> , 2021, 13, 754.	4.5	12
11	Oral delivery of topotecan in polymeric nanoparticles: Lymphatic distribution and pharmacokinetics. <i>Journal of Controlled Release</i> , 2021, 335, 86-102.	9.9	13
12	Pharmacokinetic Comparison between Methotrexate-Loaded Nanoparticles and Nanoemulsions as Hard- and Soft-Type Nanoformulations: A Population Pharmacokinetic Modeling Approach. <i>Pharmaceutics</i> , 2021, 13, 1050.	4.5	7
13	Toxicokinetics of di-isodecyl phthalate and its major metabolites in rats through the application of a developed and validated UHPLC-ESI-MS/MS method. <i>Archives of Toxicology</i> , 2021, 95, 3515-3537.	4.2	1
14	A sensitive UPLC-ESI-MS/MS method for the quantification of cinnamic acid in vivo and in vitro: application to pharmacokinetic and protein binding study in human plasma. <i>Journal of Pharmaceutical Investigation</i> , 2020, 50, 159-172.	5.3	13
15	Pharmacokinetic Comparison of Epinastine Using Developed Human Plasma Assays. <i>Molecules</i> , 2020, 25, 209.	3.8	3
16	Enhanced Lymphatic Delivery of Methotrexate Using W/O/W Nanoemulsion: In Vitro Characterization and Pharmacokinetic Study. <i>Pharmaceutics</i> , 2020, 12, 978.	4.5	28
17	Pharmacokinetic comparison with different assays for simultaneous determination of cis-, trans-cefprozil diastereomers in human plasma. <i>Journal of Pharmaceutical Analysis</i> , 2020, 11, 351-363.	5.3	0
18	Toxicokinetics of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rats: UPLC-ESI-MS/MS method development for the simultaneous determination of diisobutyl phthalate and its major metabolite, monoisobutyl phthalate, in rat plasma, urine, feces, and 11 various tissues collected from a toxicokinetic study. <i>Food and Chemical Toxicology</i> , 2020, 145, 111747.	3.6	8

#	ARTICLE	IF	CITATIONS
19	Simultaneous determination of three iridoid glycosides of <i>Rehmannia glutinosa</i> in rat biological samples using a validated hydrophilic interaction UHPLC-MS/MS method in pharmacokinetic and in vitro studies. <i>Journal of Separation Science</i> , 2020, 43, 4148-4161.	2.5	9
20	Pharmacokinetic Comparison of Three Different Administration Routes for Topotecan Hydrochloride in Rats. <i>Pharmaceutics</i> , 2020, 13, 231.	3.8	5
21	Banhahubak-Tang Tablet, a Standardized Medicine Attenuates Allergic Asthma via Inhibition of Janus Kinase 1 (JAK1)/ Signal Transducer and Activator of Transcription 6 (STAT6) Signal Pathway. <i>Molecules</i> , 2020, 25, 2206.	3.8	9
22	Gender differences in pharmacokinetics of perfluoropentanoic acid using non-linear mixed-effect modeling in rats. <i>Archives of Toxicology</i> , 2020, 94, 1601-1612.	4.2	5
23	A Novel Eye Drop Candidate for Age-Related Macular Degeneration Treatment: Studies on its Pharmacokinetics and Distribution in Rats and Rabbits. <i>Molecules</i> , 2020, 25, 663.	3.8	4
24	Response to Translational toxicology of sex specific PFNA clearance in rat and human. <i>Archives of Toxicology</i> , 2020, 94, 649-650.	4.2	0
25	Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects. <i>Pharmaceutics</i> , 2020, 12, 374.	4.5	9
26	Simultaneous measurement of epinastine and its metabolite, 9,13-bisdehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies. <i>Biomedical Chromatography</i> , 2020, 34, e4848.	1.7	2
27	Risk assessment for humans using physiologically based pharmacokinetic model of diethyl phthalate and its major metabolite, monoethyl phthalate. <i>Archives of Toxicology</i> , 2020, 94, 2377-2400.	4.2	26
28	Simultaneous determination of fourteen main active components in Gumiganghwal-tang tablet by using a newly developed UPLC-ESI-MS/MS method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1126-1127, 121743.	2.3	3
29	Preparation and In Vitro/In Vivo Characterization of Polymeric Nanoparticles Containing Methotrexate to Improve Lymphatic Delivery. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3312.	4.1	53
30	Population Pharmacokinetics of Cis-, Trans-, and Total Cefprozil in Healthy Male Koreans. <i>Pharmaceutics</i> , 2019, 11, 531.	4.5	8
31	Response to Hethey et al., 2019 letter to the editor in archives of toxicology. <i>Archives of Toxicology</i> , 2019, 93, 3033-3035.	4.2	1
32	Gender differences in pharmacokinetics and tissue distribution of 4-n-nonylphenol in rats. <i>Archives of Toxicology</i> , 2019, 93, 3121-3139.	4.2	16
33	A novel and sensitive UPLC-MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies. <i>Biomedical Chromatography</i> , 2019, 33, e4627.	1.7	2
34	Simultaneous determination of diethyl phthalate and its major metabolite, monoethyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study by ultrahigh performance liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 173, 108-119.	2.8	10
35	Comparison of UPLC-MS/MS and HPLC-UV methods for the determination of zaltoprofen in human plasma. <i>Journal of Pharmaceutical Investigation</i> , 2019, 49, 613-624.	5.3	9
36	Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling. <i>Pharmaceutics</i> , 2019, 11, 168.	4.5	36

#	ARTICLE	IF	CITATIONS
37	Exploring sex differences in human health risk assessment for PFNA and PFDA using a PBPK model. Archives of Toxicology, 2019, 93, 311-330.	4.2	28
38	Sex-specific risk assessment of PFHxS using a physiologically based pharmacokinetic model. Archives of Toxicology, 2018, 92, 1113-1131.	4.2	22
39	Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. European Journal of Pharmaceutical Sciences, 2018, 118, 154-164.	4.0	4
40	Pharmacokinetic Profile of Kaurenoic Acid after Oral Administration of Araliae Continentalis Radix Extract Powder to Humans. Pharmaceutics, 2018, 10, 253.	4.5	1
41	Simultaneous UPLC-MS/MS determination of four components of Socheongryong-tang tablet in human plasma: Application to pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1095, 214-225.	2.3	13
42	Soft- and hard-lipid nanoparticles: a novel approach to lymphatic drug delivery. Archives of Pharmacal Research, 2018, 41, 797-814.	6.3	22
43	Pharmacokinetic-Pharmacodynamic Model for the Testosterone-Suppressive Effect of Leuprolide in Normal and Prostate Cancer Rats. Molecules, 2018, 23, 909.	3.8	6
44	Simultaneous Determination of Decursin, Decursinol Angelate, Nodakenin, and Decursinol of Angelica gigas Nakai in Human Plasma by UHPLC-MS/MS: Application to Pharmacokinetic Study. Molecules, 2018, 23, 1019.	3.8	11
45	Bioequivalence of a fixed-dose repaglinide/metformin combination tablet and equivalent doses of repaglinide and metformin tablets. International Journal of Clinical Pharmacology and Therapeutics, 2018, 56, 292-300.	0.6	2
46	Simultaneous determination of imperatorin and its metabolite xanthotoxol in rat plasma and urine by LC-MS/MS and its application to pharmacokinetic studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1044-1045, 30-38.	2.3	11
47	Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 291-303.	1.8	7
48	Development of new clean-up method for UPLC-MS/MS analysis of leuprolide. Journal of Pharmaceutical Investigation, 2017, 47, 531-540.	5.3	8
49	Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1. Journal of Pharmacokinetics and Pharmacodynamics, 2017, 44, 567-579.	1.8	6
50	A sensitive UHPLC-MS/MS method for the simultaneous quantification of three lignans in human plasma and its application to a pharmacokinetic study. Journal of Separation Science, 2017, 40, 3430-3439.	2.5	9
51	Preparation and Evaluation of Solid-Self-Emulsifying Drug Delivery System Containing Paclitaxel for Lymphatic Delivery. Journal of Nanomaterials, 2016, 2016, 1-14.	2.7	25
52	Pharmacokinetic evaluation of paeoniflorin after oral administration of Paeoniae Radix extract powder to healthy Korean subjects using UPLC-MS/MS. Journal of Pharmaceutical Investigation, 2016, 46, 273-282.	5.3	3
53	Gender differences in pharmacokinetics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances in rats. Food and Chemical Toxicology, 2016, 97, 243-255.	3.6	72
54	Effect of genetic polymorphisms on the interplay of P-glycoprotein transporter and cytochrome P450 enzymes: Pharmacokinetics of risperidone. Asian Journal of Pharmaceutical Sciences, 2016, 11, 31-32.	9.1	0

#	ARTICLE	IF	CITATIONS
55	Preparation and Evaluation of PEGylated and Folate-PEGylated Liposomes Containing Paclitaxel for Lymphatic Delivery. <i>Journal of Nanomaterials</i> , 2015, 2015, 1-10.	2.7	11
56	Sensitive liquid chromatography-tandem mass spectrometry method for the simultaneous determination of benzyl butyl phthalate and its metabolites, monobenzyl phthalate and monobutyl phthalate, in rat plasma, urine, and various tissues collected from a toxicokinetic study. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 7391-7400.	3.7	8
57	Self-Emulsifying Drug Delivery System for Enhancing Bioavailability and Lymphatic Delivery of Tacrolimus. <i>Journal of Nanoscience and Nanotechnology</i> , 2015, 15, 1831-1841.	0.9	17
58	Nano-Sized Drug Delivery Systems for Lymphatic Delivery. <i>Journal of Nanoscience and Nanotechnology</i> , 2014, 14, 868-880.	0.9	23
59	Simultaneous determination of puerarin and its active metabolite in human plasma by UPLC-MS/MS: Application to a pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 971, 64-71.	2.3	24
60	Bioequivalence of Torad tablet 5Âmg to Torem tablet 5Âmg (torasemide 5Âmg). <i>Journal of Pharmaceutical Investigation</i> , 2013, 43, 153-159.	5.3	3
61	Influences of Organic Cation Transporter Polymorphisms on the Population Pharmacokinetics of Metformin in Healthy Subjects. <i>AAPS Journal</i> , 2013, 15, 571-580.	4.4	66
62	Bioequivalence of Samchundang Berastolin tablet to Jeil Berasil tablet (beraprost sodium 20Â¼g). <i>Journal of Pharmaceutical Investigation</i> , 2013, 43, 251-257.	5.3	0
63	Scrub Typhus Meningitis or Meningoencephalitis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 89, 1206-1211.	1.4	40
64	Simultaneous determination of morniflumate and its major active metabolite, niflumic acid, in human plasma by high-performance liquid chromatography in stability and pharmacokinetic studies. <i>Biomedical Chromatography</i> , 2013, 27, 1438-1443.	1.7	7
65	Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2012, 39, 329-341.	1.8	24
66	Scrub typhus meningoencephalitis occurring during doxycycline therapy for <i>Orientia tsutsugamushi</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 271-274.	1.8	19
67	Evaluation of PEG-Transferrin-PEI Nanocomplex as a Gene Delivery Agent. <i>Journal of Nanoscience and Nanotechnology</i> , 2011, 11, 7078-7081.	0.9	10
68	Influence of <i>ABCB1</i> genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with <i>CYP2D6</i> . <i>British Journal of Pharmacology</i> , 2011, 164, 433-443.	5.4	41
69	Population pharmacokinetic analysis of glimepiride with CYP2C9 genetic polymorphism in healthy Korean subjects. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 889-898.	1.9	15
70	Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. <i>Archives of Pharmacal Research</i> , 2011, 34, 1817-1828.	6.3	16
71	Development of novel sibutramine base-loaded solid dispersion with gelatin and HPMC: Physicochemical characterization and pharmacokinetics in beagle dogs. <i>International Journal of Pharmaceutics</i> , 2010, 397, 225-230.	5.2	37
72	The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. <i>Biomaterials</i> , 2010, 31, 2371-2379.	11.4	171

#	ARTICLE	IF	CITATIONS
73	Population pharmacokinetic analysis of cilostazol in healthy subjects with genetic polymorphisms of CYP3A5, CYP2C19 and <i>ABC1</i> . British Journal of Clinical Pharmacology, 2010, 69, 27-37.	2.4	43
74	Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 164-171.	4.3	79
75	Influence of ABC1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. Neuroscience, 2010, 169, 378-387.	2.3	19
76	Nano-sized Drug Carriers and Key Factors for Lymphatic Delivery. Journal of Pharmaceutical Investigation, 2010, 40, 75-82.	5.3	2
77	Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: A randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers. Clinical Therapeutics, 2009, 31, 2712-2721.	2.5	11
78	Determination of ibudilast in human serum by high-performance liquid chromatography for pharmacokinetic study. Biomedical Chromatography, 2009, 24, n/a-n/a.	1.7	0
79	Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems. International Journal of Pharmaceutics, 2009, 374, 66-72.	5.2	222
80	Haplotype Analysis and Single Nucleotide Polymorphism Frequency of Organic Cation Transporter Gene (OCT1 and 2) in Korean Subjects. Journal of Korean Pharmaceutical Sciences, 2009, 39, 345-351.	0.0	2
81	Haplotype Analysis and Single Nucleotide Polymorphism Frequency of PEPT1 Gene (Exon 5 and 16) in Korean. Journal of Korean Pharmaceutical Sciences, 2009, 39, 411-416.	0.0	1
82	Preparation and in Vivo Evaluation of Piroxicam-Loaded Gelatin Microcapsule by Spray Drying Technique. Biological and Pharmaceutical Bulletin, 2008, 31, 1284-1287.	1.4	20
83	The Effect of MDR1 G2677T/A polymorphism on pharmacokinetics of gabapentin in healthy Korean subjects. Archives of Pharmacal Research, 2007, 30, 96-101.	6.3	11
84	Improvement and validation of an HPLC method for examining the effects of the MDR1 gene polymorphism on sparfloxacin pharmacokinetics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 834, 84-92.	2.3	5
85	Controlled release of cyclosporin A from liposomes-in-microspheres as an oral delivery system. Biotechnology and Bioprocess Engineering, 2006, 11, 526-529.	2.6	7
86	Physicochemical characterization of poly(l-lactic acid) and poly(d,l-lactide-co-glycolide) nanoparticles with polyethylenimine as gene delivery carrier. International Journal of Pharmaceutics, 2005, 298, 255-262.	5.2	115
87	Biodistribution and genotoxicity of transferrin-conjugated liposomes/DNA complexes in mice. Macromolecular Research, 2005, 13, 218-222.	2.4	5
88	Preparation and mucoadhesive test of CSA-loaded liposomes with different characteristics for the intestinal lymphatic delivery. Biotechnology and Bioprocess Engineering, 2005, 10, 516-521.	2.6	9
89	Hydrophilic interaction liquid chromatography-tandem mass spectrometry for the determination of levosulpiride in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 809, 345-350.	2.3	35
90	Gene Expression Changes Associated with Sustained p16 Expression in Hepatocellular Carcinoma Cells. Immune Network, 2004, 4, 237.	3.6	0

#	ARTICLE	IF	CITATIONS
91	Self-assembled nanoparticles of hydrophobically-modified polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. <i>European Journal of Pharmaceutical Sciences</i> , 2003, 18, 165-173.	4.0	224
92	Determination of tiotropium in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 796, 395-400.	2.3	10
93	Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 798, 257-264.	2.3	13
94	Immobilization of levan fructotransferase for the production of di-fructose anhydride from levan. <i>Biotechnology Letters</i> , 2001, 23, 1335-1339.	2.2	9
95	Characteristics of levan fructotransferase from <i>Arthrobacter ureafaciens</i> K2032 and difructose anhydride IV formation from levan. <i>Enzyme and Microbial Technology</i> , 2000, 27, 212-218.	3.2	36
96	High-performance liquid chromatographic determination of trimebutine and its major metabolite, N-monodesmethyl trimebutine, in rat and human plasma. <i>Biomedical Applications</i> , 1999, 723, 239-246.	1.7	20
97	Release of adriamycin from poly(β -benzyl-L-glutamate)/poly(ethylene oxide) nanoparticles. <i>International Journal of Pharmaceutics</i> , 1999, 181, 107-115.	5.2	73
98	No effect of diltiazem on the hepatic clearance of indocyanine green in the rats. <i>Archives of Pharmacal Research</i> , 1998, 21, 411-417.	6.3	4
99	Enhanced dissolution of furosemide by coprecipitating or cogrinding with crospovidone. <i>International Journal of Pharmaceutics</i> , 1998, 175, 17-24.	5.2	53
100	Spectroscopic characterization of ibuprofen/2-hydroxypropyl- β -cyclodextrin inclusion complex. <i>International Journal of Pharmaceutics</i> , 1998, 175, 215-223.	5.2	42
101	Prolonged Release of Tegafur from S/O/W Multiple Emulsion. <i>Drug Development and Industrial Pharmacy</i> , 1998, 24, 889-894.	2.0	4
102	Preparation and characterization of cytarabine-loaded w/o/w multiple emulsions. <i>International Journal of Pharmaceutics</i> , 1995, 124, 61-67.	5.2	22
103	Enhanced dissolution rates of piroxicam from the ground mixtures with chitin or chitosan. <i>Archives of Pharmacal Research</i> , 1986, 9, 55-61.	6.3	9